Pay in 4 interest-free payments of $5.69 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
How Retatrutide Compares to Existing Therapies The progression from single to dual to triple agonist therapy represents a clear trend in obesity pharmacotherapy: Semaglutide (GLP-1 agonist): ~1517% weight loss in Phase III (STEP trials) Tirzepatide (GIP + GLP-1 dual agonist): ~2022.5% weight loss in Phase III (SURMOUNT trials) Retatrutide (GIP + GLP-1 + glucagon triple agonist): ~2629% weight loss in Phase III (TRIUMPH-4) Each additional receptor pathway appears to contribute incremental efficacy
If you miss a dose, follow the instructions provided with your medication
However, the shared signaling pathways suggest that there is an extensive crosstalk between eryptosis and RBC necroptosis
The science: how GLP-1 (and dual GLP-1/GIP) drugs work Glucagon-like peptide-1, or GLP-1, is a hormone your gut releases after you eat
US$ 20.78
US$ 21.38
US$ 27.02
US$ 24.20
US$ 26.85
US$ 29.81
